The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Clinical Discovery Awards, 2005Phase I Study of CERE-120 [Adeno-Associated Virus (AAV)-Neuturin (NTN)] to Assess the Safety and Tolerability of Intraputaminal Delivery
Objective/Rationale:
Neurotrophic factors including neurturin (NTN) have been shown to effectively augment the function and prevent the death of dopaminergic nigrostriatal neurons in animal models of... -
MJFF Research Grant, 2005Nebraska Parkinson's Disease Registry
The American Parkinson Disease Association (APDA) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) are co-funding the Nebraska Parkinson's Disease Registry with a three-year...
-
LEAPS, 2005Michael J. Fox Foundation Validation Study
The role of genetics in PD continues to be a major focus in the field and much of what we know about possible underlying mechanisms of PD cause and pathogenesis has come through studies of genes (e.g...
-
Molecular Mechanisms of Dyskinesia in Parkinson's Disease, 2005Mechanisms of Graft-Induced Dyskinesias in an Animal Model of Parkinson's Disease (Supplemental Funding)
Our ongoing project has four aims:
- To develop a model of graft-induced dyskinesia (GID) in the rat, which will provide a cost-effective tool for studying the mechanisms of this complication;
- To...
-
Community Fast Track, 2005Specific Inhibition of Nucleation of Alpha-synuclein Aggregation as a Therapeutic Strategy
There is considerable evidence that aggregates of the human brain protein alpha-synuclein are a primary cause of the loss of neurons in Parkinson's disease. We have tried to find out what initiates...
-
Community Fast Track, 2005Use of NR2D-selective NMDA Receptor Modulators in the Treatment of PD
The frontline pharmacological treatment for Parkinson’s disease is associated with serious side effects, creating a need for new therapeutic strategies. Recent evidence suggests that selective...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.